0
0
On World Sickle Cell Day, experts highlighted significant strides in the treatment of sickle cell anaemia, underscoring new therapies that could revolutionize care for patients. Traditionally, treatments like blood transfusions and medications such as hydroxyurea aimed at managing symptoms and preventing complications. However, recent innovations in medical technology are paving the way for more targeted approaches.
Dr. Meet Kumar, Clinical Director of Haematology & Bone Marrow Transplant at Marengo Asia Hospitals, Gurugram, discussed the groundbreaking potential of gene editing in clinical trials for sickle cell disease. This novel method shows promise in enabling normal haemoglobin production, which could substantially alleviate symptoms associated with the disease.
“Sickle cell disease can lead to complications such as clotting in the blood vessels of the brain, resulting in silent strokes, regular strokes, and other neurological issues,” explained Dr. Praveen Gupta, Principal Director & Chief of Neurology at Fortis Hospital. He emphasized that children with sickle cell anaemia often experience cognitive impairments, including memory and learning difficulties, along with frequent headaches and seizures.
Dr. Gaurav Kharya, Founder and Director of Cellogen Therapeutics, highlighted gene therapy as a transformative advancement in sickle cell treatment. This approach involves modifying the patient’s hematopoietic stem cells to correct the genetic defect responsible for the disease. These modified cells are then reintroduced into the patient’s body, with early clinical trials demonstrating encouraging results in improving symptoms and enhancing quality of life.
The developments discussed on World Sickle Cell Day signal a shift towards more targeted and effective treatments for this challenging disease, offering hope to patients and families affected worldwide. As research continues to advance, these innovations hold promise for improving outcomes and reducing the burden of sickle cell anaemia globally.
